--- type: "WebPage" title: "Characterization of biotherapeutic products and recombinant proteins" description: "Our expertise in the characterization of biotherapeutic products and recombinant proteins We offer comprehensive expertise in the characterization of biological macromolecules, ranging from monoclonal antibodies (mAbs) to complex bioconjugates, including glycoproteins and antibody-drug conjugates (ADCs). Our rigorous approach ensures a detailed..." resource: "https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/" tags: ["EN", "pll_66c5fcb8be0e4", "Anaïs DECAUX"] timestamp: "2026-08-20T05:35:58Z" published: "2024-08-21T14:52:19Z" language: "en" author: "Floriane Fevre" --- # Characterization of biotherapeutic products and recombinant proteins ## Our expertise in the characterization of biotherapeutic products and recombinant proteins We offer comprehensive expertise in **the characterization of biological macromolecules**, ranging from [monoclonal antibodies (mAbs)](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/analysis-characterization-monoclonal-antibodies-mabs.md) to complex bioconjugates, including glycoproteins and [antibody-drug conjugates (ADCs)](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/adc-antibody-drug-conjugates-characterization.md).  Our rigorous approach ensures a detailed analysis of your biomolecules to guarantee their identity, purity, stability, and efficacy throughout development, from research to industrial production. Thanks to advanced technologies, we deliver reliable, reproducible results that meet the strictest standards. ## Which molecules? Our services also cover the **characterization of emerging molecules** such as [peptides](https://filab.fr/en/sectors-of-activity/biopharmaceutical/peptide-aggregation-analysis-laboratory.md), [oligonucleotides](https://filab.fr/en/sectors-of-activity/biopharmaceutical/characterisation-of-cell-and-gene-therapy-products/oligonucleotide-antisense-oligonucleotide-aso-analysis.md), [bispecifics](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/analysis-characterization-bispecific-multispecific-antibodies.md), nanobodies, as well as RNA-based products, including vaccines. By providing you with a wide range of analytical methods, we help you better understand the structure and functional properties of your biological products.  Primary protein structure analysis ([amino acids](https://filab.fr/en/our-services/our-analysis-services/chemical-analysis-laboratory/analysis-amino-acids/study-amino-acids.md), [peptide mapping](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/peptide-analysis-biopharmaceutical-services.md)) by HRMS ([LC-Orbitrap](https://filab.fr/en/our-technical-resources/lc-orbitrap-analysis.md)) Spectroscopic capabilities [Analysis of post-translational modifications](https://filab.fr/services/analyse-de-modifications-post-traductionnelles-en-laboratoire.md) (deamidation, oxidation, glycation, glycosylation, isomerization, single amino acid exchanges, phosphorylation, scrambled disulfide bonds, truncation, N- and C-terminal modifications.) Mass spectrometry methods ([LC-Orbitrap](https://filab.fr/en/our-technical-resources/lc-orbitrap-analysis.md), [QTOF](https://filab.fr/en/our-technical-resources/laboratory-for-lc-qtof-analysis.md)) Whether you are developing innovative therapies or optimizing existing products, our expertise supports you at every key stage of the process. ## All of our recombinant protein analysis [Peptide analysis and characterization | Peptide mapping](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/peptide-analysis-biopharmaceutical-services.md) [Analysis and characterization of monoclonal antibodies (mAbs)](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/analysis-characterization-monoclonal-antibodies-mabs.md) [Analysis and characterization of biosimilars](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/analysis-characterization-biosimilars.md) [Analysis and characterization of glycoproteins](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/analysis-characterization-glycoproteins.md) [Proteomic analysis](https://filab.fr/en/sectors-of-activity/biopharmaceutical/laboratory-proteomic-analysis.md) [Amino acid assay](https://filab.fr/en/our-services/our-analysis-services/chemical-analysis-laboratory/analysis-amino-acids/study-amino-acids.md) Secondary & tertiary structure analysis: [Circular dichroism](https://filab.fr/en/sectors-of-activity/biopharmaceutical/measurement-circular-dichroism-cd.md) (CD), [thermal stability](https://filab.fr/nos-prestations/analyse/laboratoire-caracterisation-des-materiaux/laboratoire-analysis-thermiques-thermogravimetriques/)... [Identification of PTMs](https://filab.fr/services/analyse-de-modifications-post-traductionnelles-en-laboratoire.md) [Enzyme analysis in the laboratory](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/enzyme-analysis.md) [Analysis and characterization of antibody-drug conjugates (ADCs) in the laboratory](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/adc-antibody-drug-conjugates-characterization.md) [Analysis and characterization of bispecific and multispecific antibodies](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/analysis-characterization-bispecific-multispecific-antibodies.md) [Analysis and characterization of nanobodies](https://filab.fr/en/sectors-of-activity/biopharmaceutical/biotherapeutic-recombinant-protein-characterization/analysis-characterization-nanobodies.md) Detection and quantification of [Host Cell Proteins (HCP)](https://filab.fr/en/sectors-of-activity/biopharmaceutical/host-cell-protein-hcp-testing-analysis-laboratory.md) Analysis of elemental impurities ([ICH Q3D](https://filab.fr/nos-prestations/analyse/laboratoire-analysis-ich-q3d/) / [](https://filab.fr/en/our-services/our-analysis-services/analysis-usp-233-laboratory.md)) Identification of [glycosylations](https://filab.fr/en/sectors-of-activity/biopharmaceutical/glycosylation-analysis.md) [Quality control by Nanodrop](https://filab.fr/en/dna-rna-and-protein-analysis-by-nanodrop-in-the-laboratory.md) ![](https://filab.fr/wp-content/uploads/2024/08/shutterstock_2048548355-biopharma.jpg) ## FAQ Why characterize recombinant proteins? The **characterization of recombinant proteins** makes it possible to confirm the structure, folding, molecular mass, and biological activity of a protein produced by genetic engineering. This step is crucial for validating the efficiency and reproducibility of bioprocesses. Which molecules can FILAB analyze? Our services also cover the characterization of emerging molecules such as peptides, oligonucleotides, bispecifics, nanobodies...